Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529800 | 1.00 | SLC6A3 (0.31) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL5787963 | 1.00 | SLC6A3 (0.31) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL95266 | 0.95 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL3008891 | 0.76 | TACR1 (0.36) | LMNATSHR | |
| SCHEMBL5785839 | 0.75 | — | — | |
| SCHEMBL1869194 | 0.75 | — | — | |
| SCHEMBL2069121 | 0.72 | CPN1 (0.34) | — | |
| SCHEMBL1771338 | 0.70 | SLC6A2 (0.45) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL16921033 | 0.69 | SLC6A2 (0.39) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5485976 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2913333-A1 | 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-6939891-B2 | Nitrogen compounds such as N-(4-Fluorophenyl)-N'-[(R)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea, used as analgesics | SMITHKLINE BEECHAM, PLC (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | TRPV1, UTS2R, GPR17 | SLC6A3 1412/4885SLC6A2 1013/4885SLC6A4 1195/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | SLC6A3 974/4885SLC6A2 806/4885SLC6A4 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.